CSL Reports Five-Year Efficacy of HEMGENIX, Benefiting 75 Patients
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 11 hour ago0mins
- Durable Efficacy: The HOPE-B study shows that 94% of patients remained free from continuous prophylaxis treatment five years after a single infusion of HEMGENIX, demonstrating the therapy's long-term efficacy and safety.
- Stable Factor Activity: At five years, mean factor IX activity levels were maintained at 36.1%, not only confirming HEMGENIX's effectiveness but also enhancing patients' quality of life by reducing bleeding episodes.
- Global Adoption: More than 75 individuals across eight countries have received HEMGENIX, reflecting its growing acceptance and recognition worldwide, which is likely to drive market demand further.
- Future Monitoring Plans: Although the five-year data from the HOPE-B study is complete, participants will continue to be monitored in the IX-TEND 222-3003 study, ensuring the accumulation of long-term efficacy and safety data.
CSL.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CSL
Wall Street analysts forecast CSL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSL is 382.67 USD with a low forecast of 356.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 322.800
Low
356.00
Averages
382.67
High
400.00
Current: 322.800
Low
356.00
Averages
382.67
High
400.00
JPMorgan
Overweight
downgrade
$410 -> $400
2025-10-30
Reason
JPMorgan
Price Target
$410 -> $400
2025-10-30
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Carlisle to $400 from $410 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q3 report.
Truist
Keith Hughes
Hold
downgrade
$350 -> $340
2025-10-30
Reason
Truist
Keith Hughes
Price Target
$350 -> $340
2025-10-30
downgrade
Hold
Reason
Truist analyst Keith Hughes lowered the firm's price target on Carlisle to $340 from $350 and keeps a Hold rating on the shares. The company had put some cautionary language about business in a conference presentation last month that brought down estimates, and while its Q3 results came in above views, its Q4 guide was a good bit below and will result in the second half estimates falling notably, the analyst tells investors in a research note.
Vertical Research
Adam Baumgarten
initiated
$356
2025-10-20
Reason
Vertical Research
Adam Baumgarten
Price Target
$356
2025-10-20
initiated
Reason
Vertical Research analyst Adam Baumgarten initiated coverage of Carlisle with a Hold rating and $356 price target.
Truist
Keith Hughes
Hold
downgrade
$380 -> $350
2025-09-22
Reason
Truist
Keith Hughes
Price Target
$380 -> $350
2025-09-22
downgrade
Hold
Reason
Truist analyst Keith Hughes lowered the firm's price target on Carlisle to $350 from $380 and keeps a Hold rating on the shares. Negative commentary on markets and changes in distribution ownership discussed in the company's slides at a recent investor conference has raised questions on near-term results, the analyst tells investors in a research note. Investors will likely at least stay away from the shares until this situation is cleared up with potential for more downside pressure, the firm added.
See All Ratings
About CSL
Carlisle Companies Incorporated is a manufacturer and supplier of building envelope products and solutions that enable energy efficiency in buildings. Its segments include Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The CCM segment produces a complete line of energy-efficient single-ply roofing products and warranted roof systems and accessories for the commercial building industry, including ethylene propylene diene monomer (EPDM), thermoplastic polyolefin (TPO) and polyvinyl chloride (PVC) membrane, polyisocyanurate (polyiso) insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. CWT segment produces building envelope solutions that drive energy efficiency and sustainability in commercial and residential applications. Its products include waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid and sheet applied air/vapor barriers and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of HEMGENIX's five-year efficacy results in the HOPE-B study?
How does maintaining a factor IX activity level of 36.1% benefit patients?
Will HEMGENIX's global adoption continue to grow in the next five years?
How might the reduced bleeding rates impact healthcare costs in the future?